The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia

被引:54
作者
Xiong, Peng [1 ,2 ]
Zeng, Yong [2 ]
Wan, Jing [2 ,3 ]
Huang, Diana XiaoHan
Tan, Deyong [1 ]
Lu, Jin [2 ]
Xu, Fei [2 ]
Li, Hong Yi [2 ]
Zhu, Zuxin [2 ]
Ma, Mingxing [1 ]
机构
[1] Yunnan Univ, Sch Life Sci, Kunming 650031, Yunnan, Peoples R China
[2] Kunming Med Coll, Affiliated Hosp 1, Dept Psychiat, Kunming 650031, Yunnan, Peoples R China
[3] Weihai Jingqu Hosp, Dept Clin Psychol, Weihai 264200, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Schizophrenia; Nerve growth factor (NGF); Interleukin-2 (IL-2); Receiver operating characteristic (ROC); Diagnostic efficiency; NERVE GROWTH-FACTOR; NEUROTROPHIC FACTORS; INTERLEUKIN-2; PRODUCTION; DEPRESSION; BRAIN; CYTOKINES; ASSOCIATION; EXPRESSION; DISORDERS; SYMPTOMS;
D O I
10.1016/j.psychres.2010.12.017
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Development of reliable diagnostic bio-markers for schizophrenia remains a diagnostic challenge. Serum NGF and IL-2 were analyzed to examine the diagnostic efficiency and predictive capability of these two biomarkers in relation to schizophrenia diagnosis. Thirty neuroleptic naive subjects with first-episode schizophrenia. thirty patients with major depressive disorder (MDD) and twenty-eight healthy control subjects participated in the study. One-way ANOVA demonstrated significantly lower serum IL-2 and NGF among schizophrenic patients and patients with MDD compared with healthy controls. Receiver operating characteristic (ROC) curve analysis was used to ascertain diagnostic efficiency of serum IL-2 and NGF levels. Area under the ROC curve (AUC) revealed a high level of differentiation between schizophrenic patients and healthy controls for both IL-2 and NGF serum concentrations. Diagnostic efficiency of combined NGF and IL-2 serum levels was also high in schizophrenic patients compared with healthy controls. Serum NGF and IL-2 are promising as potential screening or diagnostic biomarkers for schizophrenia and may be a useful adjunct for clinical assessment. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:72 / 76
页数:5
相关论文
共 62 条
  • [41] INCREASED SOLUBLE INTERLEUKIN-2 RECEPTOR CONCENTRATIONS IN SUICIDE ATTEMPTERS
    NASSBERGER, L
    TRASKMANBENDZ, L
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1993, 88 (01) : 48 - 52
  • [42] Neurobiology of depression
    Nestler, EJ
    Barrot, M
    DiLeone, RJ
    Eisch, AJ
    Gold, SJ
    Monteggia, LM
    [J]. NEURON, 2002, 34 (01) : 13 - 25
  • [43] The validity of using patient self-report to assess psychotic symptoms in schizophrenia
    Niv, Noosha
    Cohen, Amy N.
    Mintz, Jim
    Ventura, Joseph
    Young, Alexander S.
    [J]. SCHIZOPHRENIA RESEARCH, 2007, 90 (1-3) : 245 - 250
  • [44] NERVE GROWTH-FACTOR INDUCES GROWTH AND DIFFERENTIATION OF HUMAN LYMPHOCYTES-B
    OTTEN, U
    EHRHARD, P
    PECK, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (24) : 10059 - 10063
  • [45] Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome
    Parikh, V
    Evans, DR
    Khan, MM
    Mahadik, SP
    [J]. SCHIZOPHRENIA RESEARCH, 2003, 60 (2-3) : 117 - 123
  • [46] Th2 cytokine response in Major Depressive Disorder patients before treatment
    Pavón, L
    Sandoval-López, G
    Hernández, ME
    Loría, F
    Estrada, I
    Pérez, M
    Moreno, J
    Avila, U
    Leff, P
    Antón, B
    Heinze, G
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2006, 172 (1-2) : 156 - 165
  • [47] Perez-Polo J R, 1978, Birth Defects Orig Artic Ser, V14, P311
  • [48] Pulver AE, 2000, BIOL PSYCHIAT, V47, P221
  • [49] Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia
    Sarró, S
    Dueñas, RM
    Ramírez, N
    Arranz, B
    Martínez, R
    Sánchez, JM
    González, J
    Saló, L
    Miralles, L
    San, L
    [J]. SCHIZOPHRENIA RESEARCH, 2004, 68 (2-3) : 349 - 356
  • [50] The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia
    Shoval, G
    Weizman, A
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (03) : 319 - 329